JP2022516848A - Btn3a結合タンパク質及びその使用 - Google Patents
Btn3a結合タンパク質及びその使用 Download PDFInfo
- Publication number
- JP2022516848A JP2022516848A JP2021535850A JP2021535850A JP2022516848A JP 2022516848 A JP2022516848 A JP 2022516848A JP 2021535850 A JP2021535850 A JP 2021535850A JP 2021535850 A JP2021535850 A JP 2021535850A JP 2022516848 A JP2022516848 A JP 2022516848A
- Authority
- JP
- Japan
- Prior art keywords
- btn3a
- seq
- cells
- antibody
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 77
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 77
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 110
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 110
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 96
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 91
- 230000027455 binding Effects 0.000 claims description 72
- 239000012634 fragment Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 42
- 230000004913 activation Effects 0.000 claims description 41
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 claims description 31
- 238000003556 assay Methods 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 20
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 claims description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
- 238000012575 bio-layer interferometry Methods 0.000 claims description 18
- 230000035755 proliferation Effects 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000003501 co-culture Methods 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 108020001580 protein domains Proteins 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 230000001461 cytolytic effect Effects 0.000 abstract description 7
- 239000002547 new drug Substances 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 239000000427 antigen Substances 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 230000000875 corresponding effect Effects 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000012491 analyte Substances 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 102000052434 human BTN3A1 Human genes 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 12
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- -1 another antibody Proteins 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- 239000012146 running buffer Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012933 kinetic analysis Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000019420 lymphoid neoplasm Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 102000035025 signaling receptors Human genes 0.000 description 3
- 108091005475 signaling receptors Proteins 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100027155 Butyrophilin subfamily 3 member A2 Human genes 0.000 description 2
- 102100027154 Butyrophilin subfamily 3 member A3 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000984917 Homo sapiens Butyrophilin subfamily 3 member A2 Proteins 0.000 description 2
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 2
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 206010014881 enterobiasis Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 101710135378 pH 6 antigen Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002849 thermal shift Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 201000002311 trypanosomiasis Diseases 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HYCKBFLTZGORKA-HNPMAXIBSA-N 3,7-dihydropurin-6-one;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HYCKBFLTZGORKA-HNPMAXIBSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940111018 BTLA antagonist Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101150084279 TM gene Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 241000203826 Tropheryma whipplei Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000002804 saturated mutagenesis Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229950003999 tafluposide Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
i.配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)と、
ii.配列番号4のL-CDR1、配列番号5又は配列番号17のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)と
を有する少なくともBTN3A抗体断片を含む、単離されたBTN3A結合タンパク質であって、以下の特性:
i.バイオ層干渉法(BLI)技術によって測定される場合、10nM以下のKD、好ましくは5nM以下のKDでヒトBTN3A1と結合すること、並びに/又は、
ii.ダウディ(Daudi)若しくはSKOV-3細胞などの癌細胞との共培養物中におけるγδ T細胞(Vγ9Vδ2 T細胞など)の活性化を、CD107脱顆粒アッセイにおいて測定される場合、10nM以下、好ましくは1nM以下のEC50で誘導すること、並びに/又は
iii.PBMC内のγδ T細胞(典型的にはVγ9Vδ2 T細胞)の活性化及び増殖を誘導すること
を有する、BTN3A結合タンパク質に関する。
(i)配列番号18の重鎖可変領域と、
(ii)配列番号19の軽鎖可変領域と
を含む。
本開示をより容易に理解することができるように、特定の用語をまず定義する。追加の定義が詳細な説明の全体にわたって記載されている。
具体的な一実施形態では、本開示のBTN3A結合タンパク質は、
(i)配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)と、
(ii)配列番号4のL-CDR1、配列番号5のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)と
を有する少なくともBTN3A抗体断片を含む。
(i)配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)と、
(ii)配列番号4のL-CDR1、配列番号17のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)と
を有する少なくともBTN3A抗体断片を含む。
(i)配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)、たとえば配列番号7のVHと、
(ii)配列番号4のL-CDR1、配列番号5のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)、たとえば配列番号8のVLと
を含むscFv、Fab、又は(Fab’)2断片である。
(i)配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)、たとえば配列番号18のVHと、
(ii)配列番号4のL-CDR1、配列番号17のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)、たとえば配列番号19のVLと
を含むscFv、Fab、又は(Fab’)2断片である。
(i)バイオ層干渉法(BLI)技術によって若しくは表面プラズモン共鳴によって測定される場合、10nM以下のKD、好ましくは5nM以下のKDでヒトBTN3A1と結合すること、
(ii)癌細胞(ダウディ及び/若しくはSKOV-3細胞など)との共培養物中におけるγδ T細胞(典型的にはVγ9Vδ2 T細胞)の活性化を、CD107脱顆粒アッセイにおいて測定される場合、10nM以下、好ましくは1nM以下のEC50で誘導すること、並びに/又は
(iii)PBMC内のγδ T細胞(典型的にはVγ9Vδ2 T細胞)の活性化及び増殖を誘導すること。
(i)配列番号18の重鎖可変領域と、
(ii)配列番号19の軽鎖可変領域と
を含むヒト化BTN3A抗体断片である。
(i)配列番号18の重鎖可変領域と、
(ii)配列番号19の軽鎖可変領域と
を含むscFv断片であるヒト化BTN3A結合抗体断片に関する。
本開示のBTN3A結合タンパク質は、
(i)配列番号1のH-CDR1、配列番号2のH-CDR-2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)と、
(ii)配列番号4のL-CDR1、配列番号5又は配列番号17のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)と
を有する少なくともBTN3A結合抗体断片を含む。
(i)表面プラズモン共鳴によって若しくはバイオ層干渉法(BLI)技術によって測定される場合、10nM以下のKD、好ましくは5nM以下のKDでヒトBTN3A1と結合すること、並びに/又は、
(ii)癌細胞(ダウディ若しくはSKOV-3細胞など)との共培養物中におけるγδ T細胞(典型的にはVγ9Vδ2 T細胞)の活性化を、CD107脱顆粒アッセイにおいて測定される場合、10nM以下、好ましくは1nM以下、たとえば0.1nM以下のEC50で誘導すること、並びに/又は
(iii)PBMC内のγδ T細胞(典型的にはVγ9Vδ2 T細胞)の活性化及び増殖を誘導すること。
Ab103.2-L-X (I)
[式中、
Ab103.2は、以前のセクション中に開示した活性化BTN3A抗体断片、たとえば、scFv又はFab断片であり、
Lは、共有結合又はリンカー、典型的にはペプチドリンカーであり、
Xはポリペプチド鎖である]。
別の態様では、以前のセクション中に開示したBTN3A結合タンパク質及び/又は活性化BTN3A抗体断片を含む二重特異性又は多特異性分子を、本明細書中にさらに開示する。
本開示のBTN3A抗体断片、BTN3A結合タンパク質、又は二重特異性分子をコードしている核酸分子も本明細書中に開示する。
本開示のBTN3A結合抗体断片、BTN3A結合タンパク質、又は二重特異性分子は、たとえば、当分野で周知のように組換えDNA技法及び遺伝子形質移入方法の組合せを使用して、宿主細胞トランスフェクトーマ中で産生させることができる(Morrison、1985年)。
別の態様では、本開示は、薬学的に許容される担体と一緒に製剤化された、上記開示した活性化BTN3A抗体断片及び/又はBTN3A結合タンパク質又は二重特異性分子を含有する組成物、たとえば医薬組成物を提供する。そのような組成物は、上述の抗体断片、又は結合タンパク質、又は二重特異性分子のうちの1つ又は(たとえば2つ以上の異なるものの)組合せを含んでいてもよい。
本開示の活性化BTN3A抗体断片、BTN3A結合タンパク質、及び二重特異性分子は、in vitro及びin vivoの診断的及び治療的な有用性を有する。
治療上有効な量の本開示のBTN3A抗体断片又は結合タンパク質又は二重特異性分子と、たとえば上述した抗ウイルス剤若しくは抗増殖剤又は免疫治療剤(抗PD-1若しくは抗BTLA抗体など)である、少なくとも1つの第2の原薬、前記第2の原薬との、共投与、たとえば同時投与又は連続投与を含む、上記定義した方法。
(a)対象の血液試料から、Vγ9Vδ2 T細胞を含めたγδ T細胞(たとえばVγ9Vδ2 T細胞)を含む血液細胞、たとえば、PBMCを単離すること、
(b)in vitroで、前記γδ T細胞を、本明細書中に開示した活性化BTN3A抗体断片、BTN3A結合タンパク質、又は二重特異性分子のうちの任意の1つの存在下で、腫瘍、典型的にはBTN3A発現腫瘍細胞又は補助細胞の少なくともいずれかと増大させることと、
(c)増大させたγδ T細胞を収集することと、
(d)任意選択で、増大させたγδ T細胞を製剤化し、治療上効率的な量の前記γδ T細胞(したがって、典型的にはVγ9Vδ2 T細胞)を対象に投与することと
を含む方法に関する。
I.様々な様式(IgG、Fab、及びF(ab’)2)の103.2抗体のキメラバージョンを用いて行った実験
1.Fab及びF(ab’)2断片の調製
a.F(ab’)2作製のためのペプシン消化
50%スラリー中の固定ペプシン(サーモサイエンティフィック(Thermo Scientific)キット、カタログ番号44988)を、スラリーを5000gで2分間遠沈させることによって、消化緩衝液(20mMの酢酸ナトリウム、pH4.4)へと緩衝液交換した。上清を廃棄し、スラリーを1mLの消化緩衝液に再懸濁させ、次いで、5000gで2分間さらに遠心した。このステップをさらに4回繰り返した(合計5回の樹脂洗浄)。その後、樹脂を元のスラリー体積まで消化緩衝液に再懸濁させた。
50%スラリー中の固定パパイン(サーモサイエンティフィックキット、カタログ番号20341)を、スラリーを5000gで2分間遠沈させることによって、消化緩衝液(20mMのリン酸ナトリウム、10mMのEDTA、150mMのシステイン、pH7.0)へと緩衝液交換した。上清を廃棄し、スラリーをより大きな体積の消化緩衝液に再懸濁させ、次いで、5000gで2分間さらに遠心した。このステップをさらに4回繰り返した(合計5回の樹脂洗浄)。その後、樹脂を元のスラリー体積まで消化緩衝液に再懸濁させた。
ヒトBTN3A1と結合するキメラ103.2 Fab及びF(ab’)2の親和性を評価するために、単一サイクル動力学的分析を、ビアコアT200制御ソフトウェアV2.0.1及び評価ソフトウェアV3.0(GEヘルスケア(GE Healthcare)、スウェーデン、ウプサラ)を実行中のビアコアT200(シリアル番号1909913)装置を使用して行った。すべての単一サイクル動力学的実験は、25℃で、0.1%のBSA(GEヘルスケア、英国、リトルチャルフォント)を含有するHBS-P+ランニング緩衝液(pH7.4)を用いて実行した。
本アッセイは、キメラ抗体103.2並びにそのFab及びF(ab’)2様式の、ダウディバーキットリンパ腫細胞株に対するVγ9Vδ2 T細胞の脱顆粒に対する活性化又は阻害効果を測定することからなる(Harlyら、2012年)。Vγ9Vδ2 T細胞は、健康なドナーのPBMCから、ゾレドロン酸(1μM)及びIL-2(200UI/mL)と共に11~13日間培養することによって増大させた。IL-2を5日目、8日目、及びそれ以降は2日毎に加える。Vγ9Vδ2 T細胞の百分率は、フローサイトメトリーによって、培養開始時に決定し、培養の間、少なくとも80%に到達するまで評価した。このステップで、Vγ9Vδ2 T細胞を凍結して保存した。その後、凍結Vγ9Vδ2 T細胞をダウディ細胞株に対する脱顆粒アッセイ(1:1のE:T比)において使用し、ここで、細胞は、4時間、37℃で、10μg/mLの103.2キメラ抗体及びその様々な様式の存在下で共培養する。PMA(20ng/mL)+イオノマイシン(1μg/mL)による活性化がVγ9Vδ2 T細胞の脱顆粒の陽性対照として役割を果たし、培地単独が陰性対照として役割を果たした。4時間の共インキュベーションの終わりに、細胞をフローサイトメトリーによって分析して、CD107a(LAMP-1、リソソームの関連タンパク質膜タンパク質-1)+CD107b(LAMP-2)に対して陽性であるVγ9Vδ2 T細胞の百分率を評価した。CD107は、活性化誘導性の顆粒開口分泌後に細胞表面に固定し、したがって、表面CD107の測定は、最近脱顆粒した細胞溶解性T細胞を同定するための感受性マーカーである。
1.様々なヒト化バリアントの設計及び構築
a.ヒト化可変領域配列の設計
マウス103.2抗体V領域の構造的モデルをSwiss PDBを使用して生成し、抗体の結合特性にとって必要不可欠である可能性が高い、V領域中の重要な「束縛」アミノ酸を同定するために分析した。CDR内に含有されるほとんどの残基(Kabat及びChothiaの定義をどちらも使用)が、いくつかのフレームワーク残基と一緒に重要であると考えられた。マウス103.2のVH及びVκ配列は典型的なフレームワーク残基を含有し、CDR1、2、及び3モチーフは多くのマウス抗体と比較可能である。
構造解析に基づいて、103.2ヒト化バリアントを作製するために使用することができる配列セグメントの大きな予備組を選択し、ヒトMHCクラスII対立遺伝子とのペプチド結合のin silico分析のためのiTope(商標)技術を使用して(Perryら、2008年)、及び既知の抗体配列関連T細胞エピトープのTCED(商標)を使用して(Brysonら、2010年)、分析した。ヒトMHCクラスIIに対する有意な非ヒト生殖系列結合剤であると同定された配列セグメント、又はTCED(商標)に対して有意なヒットをスコアした配列セグメントは廃棄した。これによりセグメントの縮小された組がもたらされ、これらの組合せを上述のように再度分析して、セグメント間の接続部が潜在的なT細胞エピトープを含有しないことを確実にした。選択された配列セグメントを、有意なT細胞エピトープを欠く完全なV領域配列へとアセンブルした。その後、5つの重鎖(VH1~VH5)及び4つの軽鎖(Vκ1~Vκ4)の配列を遺伝子合成及び哺乳動物細胞中での発現のために選択した。
103.2ヒト化バリアントは、ヒトIgG4(S241P、L248E)重鎖及びカッパ軽鎖のための発現ベクターシステム内にクローニングするために、隣接する制限酵素部位を有するように合成した。VH領域はMlu IとHind III制限部位の間にクローニングし、Vκ領域はBssH IIとBamH I制限部位の間にクローニングした。すべての構築体はシーケンシングによって確認した。
キメラ103.2(VH0/Vκ0)、2つの対照の組合せ(VH0/Vκ1、VH1/Vκ0)、並びにヒト化重鎖及び軽鎖の組合せ(合計23対)を、フリースタイル(FreeStyle)(商標)CHO-S細胞(サーモフィッシャー(ThermoFisher)、英国、ラフバラ)内に、対応する内毒素無含有DNAからのマックスサイト(MaxCyte)STX(登録商標)電気穿孔システム(マックスサイト(MaxCyte Inc.)、米国、ゲイザースバーグ)を使用して、一過的に形質移入した。OC-400プロセッシングアセンブリを使用して、それぞれの抗体について形質移入を行った。細胞の回収後、細胞を3×106個の細胞/mLまで、8mMのL-グルタミン(サーモフィッシャー、英国ラフバラ)及び1×ヒポキサンチン-チミジン(サーモフィッシャー、英国、ラフバラ)を含有するCD Opti-CHO培地(サーモフィッシャー、英国、ラフバラ)へと希釈した。形質移入の24時間後、培養温度を32℃まで下げ、1mMの酪酸ナトリウム(シグマ(Sigma)、英国、ドーセット)を加えた。(開始体積の)3.6%のフィード(2.5%のCHO CDエフィシェントフィードA(Efficient Feed A)(サーモフィッシャー、英国、ラフバラ)、0.5%のイーストレート(Yeastolate)(BDバイオサイエンス(BD Biosciences)、英国、オックスフォード)、0.25mMのグルタマックス(Glutamax)(サーモフィッシャー、英国、ラフバラ)、及び2g/Lのグルコース(シグマ、英国、ドーセット)を添加することによって、培養物に毎日供給した。IgG上清濃度をIgG ELISAによってモニタリングし、形質移入を、上清を収穫する14日前まで培養した。
すべての103.2ヒト化バリアントの結合を評価し、ヒトBTN3A1に対して最も高い親和性を有する抗体を選択するために、単一サイクル動力学的分析を、形質移入した細胞培養物からの上清に対して、ビアコアT200評価ソフトウェアV2.0.1(スウェーデン、ウプサラ)を実行中のビアコアT200(シリアル番号1909913)を使用して行った。
最良の親和性及び最良のiTope(商標)スコアを有する6つの103.2ヒト化バリアントをさらなる分析のために選択した。
a.競合ELISA分析
精製したバリアントを、対応するマウス抗体、103.2に対して競合しながら、組換えヒトBTN3A1-His(シノバイオロジカル カタログ番号15973-H08H)と結合することについて試験した。比較のために、キメラ(VH0/Vκ0)及び無関係のヒトIgG4(S241P、L248E)をそれぞれのプレート上で試験した。
6つの選択された103.2ヒト化バリアントの熱安定性を評価するために、蛍光に基づく熱シフトアッセイを使用して融解温度(タンパク質ドメインの50%がアンフォールドされる温度)を決定した。
複数サイクル動力学的分析を、6つの選択されたヒト化103.2バリアント(VH4/Vκ2、VH4/Vκ3、VH4/Vκ4、VH5/Vκ2、VH5/Vκ3、VH5/Vκ4)に対して、キメラ抗体及びヒト化バリアントVH1/Vκ1と共に、ビアコアT200評価ソフトウェアV2.0.1(スウェーデン、ウプサラ)を実行中のビアコアT200(シリアル番号1909913)装置を使用して行った。
ヒト化バリアントを、健康なドナーの血液から単離したヒトPBMCとの結合について特徴づけた。PBMCを、リンフォプレップ(Lymphoprep)(アクシスシールド(Axis-shield)、英国、ダンディー)密度遠心分離を使用してバフィーコートから単離した。その後、PBMCを凍結し、-80℃又は液体窒素中で必要時まで保存した。
セクションI.3.に記載したものと同じプロトコルを使用した。
すべての以下の実験は、ヒト化プロセス後に選択された、本明細書中でhu103.2とも命名された103.2 VH4/Vk4 IgG1 L247F L248E P350S dKに対応する、参照ヒト化候補を使用して行った。
セクションI.1.に記載したものと同じプロトコルを使用した。
様々な様式(Fab、F(ab’)2、及びIgG)の参照ヒト化103.2抗体(hu103.2)のヒトBTN3A1に対する親和性を評価するために、単一サイクル動力学的分析は、ビアコアT200制御ソフトウェアV2.0.1及び評価ソフトウェアV3.0(GEヘルスケア、スウェーデン、ウプサラ)を実行中のビアコアT200(シリアル番号1909913)装置を使用して行った。すべての単一サイクル動力学的実験は、25℃で、0.1%のBSA(GEヘルスケア、英国、リトルチャルフォント)を含有するHBS-P+ランニング緩衝液(pH7.4)を用いて実行した。
ヒトBTN3A1に対する様々な様式(Fab、F(ab’)2、及びIgG)のリードヒト化103.2抗体の親和性を評価するために、バイオ層干渉法技術を使用した。すべての実行(ローディング、平衡化、会合/分析物内へのセンサーの浸漬、解離、及び再生を含む)は、黒色96ウェルプレート(グレイナー(Greiner))中、30℃で、1000rpmで振盪しながら、オクテットレッド(OctetRed)96(フォルテバイオ(ForteBio))を使用して行った。FAB2Gセンサー(抗ヒトCH1、フォルテバイオ)は、まず0.2mlの動力学的緩衝液(PBS、pH7.4、0.02%のツイーン20、及び0.1%のBSA)を用いて10分間水和させ、その後、103.2抗体のヒト化バージョン又は断片(2μg/mL)をローディングした。抗体又は断片と様々な濃度のヒトBTN3A1(60、30、15、7.5、3.75、及び1.87nM)との会合を300秒間モニタリングし、解離が続いて典型的には500秒間、動力学的緩衝液中起こった。データの当てはめ及び定数の測定は、オクテットレッドシステムソフトウェア(バージョン7.1)を用いて、1:1モデルを使用して行った。標的タンパク質の非特異的結合の非存在を評価するために、無関係の抗体を用いた対照を使用した。
PBMCを3人の健康なドナーから単離し、セルトレースバイオレット色素で染色し、5日間、67nMの様々なヒト化103.2様式(IgG、Fab、及びF(ab’)2)と共に、37℃、5%のCO2でインキュベートした。その後、様々な免疫部分組の活性化及び増殖をフローサイトメトリー分析によって観察した。
セクションI.1.に記載したものと同じプロトコルを使用した。3人の異なる健康なドナーから単離したVγ9Vδ2 T細胞を増大させ、2つの異なる細胞株、すなわち、ダウディ(リンパ腫細胞株)及びSKOV-3(卵巣癌細胞株)と共に共インキュベートした。いくつかの用量の103.2の様々なヒト化バージョン(IgG、Fab、及びF(ab’)2)を本アッセイで試験した。
I.103.2 Fab及びF(ab’)2断片のキメラバージョンを用いて行った実験
1.Fab及びF(ab’)2断片の調製
Fab及びF(ab’)2断片を、QC分析のためにSDS-PAGE、分析用SEC、及びOD280nmの読取りによって分析した。精製したFab及びF(ab’)2断片について凝集は観察されなかった(データ示さず)。
ヒトBTN3A1に対するキメラ103.2 Fab及びF(ab’)2断片の親和性を、ビアコアを使用して評価した。得られた動力学的定数は、F(ab’)2断片については表1に、Fab断片については表2に列挙する。
Vγ9Vδ2 T細胞の細胞毒性を誘導するキメラ103.2断片の有効性を、Vγ9Vδ2 T細胞をダウディ細胞と共インキュベートした脱顆粒アッセイにおいて評価した。その表面でCD107を発現するVγ9Vδ2 T細胞の割合を表3に詳述する。
1.ヒト化バリアントの予備選択
合計23対のヒト化VH及びVL領域を設計し、予備選択のために生成した。
選択されたヒト化バリアントを生成し、精製し、SDS-PAGEによって分析した。典型的な抗体のプロフィールに対応するバンドがSDS-PAGE上で観察された。
まず、精製した103.2ヒト化バリアントを、マウスバージョンに対して競合しながら組換えヒトBTN3A1と結合することについて試験した。すべての試験したヒト化バリアントはキメラの2倍以内の推定IC50を有していた(データ示さず)。
1.Fab及びF(ab’)2断片の調製
Fab及びF(ab’)2断片を、QC分析のためにSDS-PAGE、分析用SEC、及びOD280nmの読取りによって分析した。精製したFab及びF(ab’)2断片について凝集は観察されなかった(データ示さず)。
様々な様式(IgG、Fab、及びF(ab’)2)のヒト化103.2抗体の、ヒトBTN3A1に対する親和性をビアコアによって評価した。得られた動力学的値は、IgG様式については表4に、F(ab’)2断片については表5に、Fab様式については表6に列挙する。
様々な様式(IgG、Fab、及びF(ab’)2)のヒト化103.2抗体の、ヒトBTN3A1に対する親和性も、オクテットレッド96を使用して行った。得られた動力学的値は表7に列挙する。
様々な様式(IgG、Fab、及びF(ab’)2)のヒト化103.2抗体(hu103.2)の、PBMC内の様々な免疫部分組活性化及び増殖に対する効果は、フローサイトメトリーを使用して様々な免疫細胞の表面で増殖及び活性化マーカーを検出することによって評価した。
様々な様式(IgG、Fab、及びF(ab’)2)のヒト化103.2抗体(hu103.2)の有効性を脱顆粒アッセイにおいて評価した。様々な用量のそれぞれの様式を試験し、EC50値を決定し、表9に列挙する。
表10及び11:本発明を実施するために有用なアミノ酸及びヌクレオチド配列の簡単な説明
Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., and Struhl, K. (1988). Current Protocols in Molecular Biology (John Wiley & Sons).
Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M., Lee, T., Pope, S.H., Riordan, G.S., and Whitlow, M. (1988). Single-chain antigen-binding proteins. Science 242, 423-426.
Blazquez, J.-L., Benyamine, A., Pasero, C., and Olive, D. (2018). New Insights Into the Regulation of Vγ9Vδ2 T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. Front. Immunol. 9.
Brennan, M., Davison, P.F., and Paulus, H. (1985). Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229, 81-83.
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., and Golstein, P. (1987). A new member of the immunoglobulin superfamily-CTLA-4. Nature 328, 267-270.
Bryson, C.J., Jones, T.D., and Baker, M.P. (2010). Prediction of Immunogenicity of Therapeutic Proteins. BioDrugs 24, 1-8.
Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., and Riley, J.L. (2004). SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology 173, 945-954.
Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine 21, 938-945.
Glennie, M.J., McBride, H.M., Worth, A.T., and Stevenson, G.T. (1987). Preparation and performance of bispecific F(ab’ gamma)2 antibody containing thioether-linked Fab’ gamma fragments. The Journal of Immunology 139, 2367-2375.
Goeddel, D.V. (1990). [1] Systems for heterologous gene expression. In Methods in Enzymology, (Academic Press), pp. 3-7.
Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. (2005). The B7 family revisited. Annu. Rev. Immunol. 23, 515-548.
Harly, C., Guillaume, Y., Nedellec, S., Peigne, C.-M., Monkkonen, H., Monkkonen, J., Li, J., Kuball, J., Adams, E.J., Netzer, S., et al. (2012). Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human Vγ9Vδ2 T-cell subset. Blood 120, 2269-2279.
Huston, J.S., Levinson, D., Mudgett-Hunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E., and Crea, R. (1988). Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. PNAS 85, 5879-5883.
Kabat, E.A., Wu, T.T., Foeller, C., Perry, H.M., and Gottesman, K.S. (1992). Sequences of Proteins of Immunological Interest (DIANE Publishing).
Karpovsky, B., Titus, J.A., Stephany, D.A., and Segal, D.M. (1984). Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. Journal of Experimental Medicine 160, 1686-1701.
Kaufman, R.J., and Sharp, P.A. (1982). Construction of a modular dihydrofolate reductase cDNA gene: analysis of signals utilized for efficient expression. Mol Cell Biol 2, 1304-1319.
Liu, M.A., Kranz, D.M., Kurnick, J.T., Boyle, L.A., Levy, R., and Eisen, H.N. (1985). Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. PNAS 82, 8648-8652.
McCafferty, J., Griffiths, A.D., Winter, G., and Chiswell, D.J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554.
Morrison, S.L. (1985). Transfectomas provide novel chimeric antibodies. Science 229, 1202-1207.
Palakodeti, A., Sandstrom, A., Sundaresan, L., Harly, C., Nedellec, S., Olive, D., Scotet, E., Bonneville, M., and Adams, E.J. (2012). The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J. Biol. Chem. 287, 32780-32790.
Paulus, H. (1985). Preparation and biomedical applications of bispecific antibodies. Behring Inst. Mitt. 118-132.
Perry, L.C.A., Jones, T.D., and Baker, M.P. (2008). New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 9, 385-396.
Remington, J.P., and Gennaro, A.R. (1995). Remington: the science and practice of pharmacy (Easton, PA: Mack Publishing).
Riley, J.L., and June, C.H. (2005). The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105, 13-21.
Sedykh, S.E., Prinz, V.V., Buneva, V.N., and Nevinsky, G.A. (2018). Bispecific antibodies: design, therapy, perspectives.
Shukla, A.A., Hubbard, B., Tressel, T., Guhan, S., and Low, D. (2007). Downstream processing of monoclonal antibodies-Application of platform approaches. Journal of Chromatography B 848, 28-39.
Stech, M., Nikolaeva, O., Thoring, L., Stocklein, W.F.M., Wustenhagen, D.A., Hust, M., Dubel, S., and Kubick, S. (2017). Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates. Scientific Reports 7, 12030.
Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., and Arai, N. (1988). SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8, 466-472.
Tosolini, M., Pont, F., Poupot, M., Vergez, F., Nicolau-Travers, M.-L., Vermijlen, D., Sarry, J.-E., Dieli, F., and Fournie, J.-J. (2017). Assessment of tumor-infiltrating TCRVγ9Vδ2 Vγ9Vδ2 lymphocyte abundance by deconvolution of human cancers microarrays. OncoImmunology 6, e1284723.
Urlaub, G., and Chasin, L.A. (1980). Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A 77, 4216-4220.
Claims (15)
- (i)配列番号1のH-CDR1、配列番号2のH-CDR2、及び配列番号3のH-CDR3を含む重鎖可変領域(VH)と、
(ii)配列番号4のL-CDR1、配列番号5又は配列番号17のL-CDR2、及び配列番号6のL-CDR3を含む軽鎖可変領域(VL)と
を有するBTN3A抗体断片を少なくとも含む、単離されたBTN3A結合タンパク質であって、以下の特性:
(i)バイオ層干渉法(BLI)技術によって測定される場合、10nM以下のKD、好ましくは5nM以下のKDでヒトBTN3A1と結合すること、並びに/又は、
(ii)癌細胞、任意選択でダウディ及び/若しくはSKOV-3細胞との共培養物中におけるγδ T細胞の活性化を、CD107脱顆粒アッセイにおいて測定される場合、10nM以下、好ましくは1nM以下のEC50で誘導すること、並びに/又は
(iii)PBMC内のVγ9Vδ2 T細胞の活性化及び増殖を誘導すること
を有する、BTN3A結合タンパク質。 - 前記BTN3A抗体断片が、
(i)配列番号18の重鎖可変領域と、
(ii)配列番号19の軽鎖可変領域と
を含む、請求項1に記載のBTN3A結合タンパク質。 - 前記BTN3A抗体断片が、scFv、Fab、又は(Fab)’2断片から選択される、請求項1又は2に記載のBTN3A結合タンパク質。
- BTN3Aとの結合について一価又は二価である、請求項1、2、又は3に記載のBTN3A結合タンパク質。
- 請求項3に記載のBTN3A抗体断片から本質的になる、たとえば、配列番号18のVHドメインと配列番号19のVLドメインとを含むscFvからなる、請求項1~4のいずれか一項に記載のBTN3A結合タンパク質。
- 1つ又は複数の追加のタンパク質ドメインと融合した前記BTN3A抗体断片を含む融合タンパク質である、請求項1~5のいずれか一項に記載のBTN3A結合タンパク質。
- 医薬品としての使用のための、請求項1~6のいずれか一項に記載のBTN3A結合タンパク質。
- 癌、たとえば、γδ T細胞を用いた処置に感受性のある癌の処置における使用のための、請求項7に記載のBTN3A結合タンパク質。
- (i)固形腫瘍及び/又は(ii)血液癌の処置における使用のための、請求項8に記載のBTN3A結合タンパク質。
- 請求項1~6のいずれか一項に記載のBTN3A結合タンパク質を、薬学的に許容される賦形剤、希釈剤、又は担体のうちの1つ又は複数と組み合わせて含み、任意選択で他の活性成分を含む、医薬組成物。
- 前記BTN3A結合タンパク質をコードしている1つ又は複数の核酸を含む、宿主細胞中における請求項1~6のいずれか一項に記載のBTN3A結合タンパク質の組換え産生のための発現ベクター。
- 前記核酸が、請求項2に記載の前記BTN3A抗体断片の重鎖及び軽鎖のコード配列、典型的には配列番号15及び16を含む、請求項11に記載の発現ベクター。
- 請求項11又は12に記載の発現ベクターを含む宿主細胞。
- 請求項1~6のいずれか一項に記載のBTN3A結合タンパク質を産生する方法であって、(i)請求項13に記載の宿主細胞を培養して、前記宿主細胞により前記BTN3A結合タンパク質を発現させるステップと、任意選択で、(ii)前記BTN3A結合タンパク質を精製し、前記BTN3A結合タンパク質を製剤化するステップとを含む方法。
- γδ T細胞の増殖及び/又は活性化をex vivo又はin vivoで誘導する方法であって、効率的な量の請求項1~6のいずれか一項に記載のBTN3A結合タンパク質を、前記γδ T細胞と、任意選択でBTN3A発現腫瘍細胞などの他のBTN3A発現細胞の存在下で接触させるステップを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306845.1 | 2018-12-26 | ||
EP18306845 | 2018-12-26 | ||
PCT/EP2019/087040 WO2020136218A1 (en) | 2018-12-26 | 2019-12-26 | Btn3a binding proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022516848A true JP2022516848A (ja) | 2022-03-03 |
Family
ID=65200545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021535850A Pending JP2022516848A (ja) | 2018-12-26 | 2019-12-26 | Btn3a結合タンパク質及びその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220073619A1 (ja) |
EP (1) | EP3902827A1 (ja) |
JP (1) | JP2022516848A (ja) |
CN (1) | CN113412281A (ja) |
AU (1) | AU2019412754A1 (ja) |
WO (1) | WO2020136218A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013333A1 (en) * | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
AU2022378932A1 (en) | 2021-10-27 | 2024-05-02 | Assistance Publique Hopitaux De Marseille | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
WO2023217743A1 (en) | 2022-05-10 | 2023-11-16 | Imcheck Therapeutics | Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
WO2010106051A1 (en) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Btla antibodies and uses thereof |
AR077594A1 (es) | 2009-07-31 | 2011-09-07 | Organon Nv | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
-
2019
- 2019-12-26 AU AU2019412754A patent/AU2019412754A1/en active Pending
- 2019-12-26 WO PCT/EP2019/087040 patent/WO2020136218A1/en unknown
- 2019-12-26 JP JP2021535850A patent/JP2022516848A/ja active Pending
- 2019-12-26 EP EP19831759.6A patent/EP3902827A1/en active Pending
- 2019-12-26 US US17/418,017 patent/US20220073619A1/en active Pending
- 2019-12-26 CN CN201980091602.3A patent/CN113412281A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220073619A1 (en) | 2022-03-10 |
AU2019412754A1 (en) | 2021-07-01 |
WO2020136218A1 (en) | 2020-07-02 |
EP3902827A1 (en) | 2021-11-03 |
CN113412281A (zh) | 2021-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102536145B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
US9567399B1 (en) | Antibodies and immunocytokines | |
WO2020135201A1 (zh) | 一种抗体及其用途 | |
JP2022516848A (ja) | Btn3a結合タンパク質及びその使用 | |
US11970538B2 (en) | Multispecific binding constructs against checkpoint molecules and uses thereof | |
EP4039704A1 (en) | Anti-pd-1 antibody and use thereof | |
JP2021533204A (ja) | 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用 | |
CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
JP2023182689A (ja) | 抗cldn4-抗cd137二重特異性抗体 | |
CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
WO2023174405A1 (zh) | Claudin18.2人源化抗体及其应用 | |
CN114667296B (zh) | 一种双特异性抗体及其用途 | |
CN114761042A (zh) | Il-38特异性抗体 | |
WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
CN110407942B (zh) | 针对kn044的单域抗体 | |
US20220064284A1 (en) | Anti-idiotypic antibodies against anti-gprc5d antibodies | |
US20220162305A1 (en) | Antibodies having specificity for btn2 and uses thereof | |
CN116478288A (zh) | 红细胞弱结合型人源化cd47抗体及其应用 | |
CA3231553A1 (en) | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody | |
JP2024509369A (ja) | 抗pd-l1抗体及びその使用 | |
CA3231320A1 (en) | Protein specifically binding to pd-1 and pharmaceutical use thereof | |
CN117794952A (zh) | 抗tigit抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221216 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240227 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240514 |